Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii

Journal of Infection

Volumn 64, Issue 1, 2012, Pages 119-121

  Rodríguez, Carlos Hernan ^a   Barberis, Claudia ^a   Nastro, Marcela ^a   Bombicino, Karina ^a   Granados, Gabriela ^a   Vay, Carlos ^a   Famiglietti, Angela ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; RIFAMPICIN; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CASE REPORT; CHILD; CONCENTRATION RESPONSE; DILUTION; DISEASE ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; RECOMMENDED DRUG DOSE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84455169521     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.10.007     Document Type: Letter

References (12)

1. Yau W., Owen R., Poudyal A., Bell J., Turnidge J., Yu H., et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009, 58:138-144. doi:10.106/j.jinf.2008.11.002.
2. Rodriguez C.H., Bombicino K., Granados G., Nastro M., Vay C., Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diag Microbiol Inf Dis 2009, 65:188-191. doi:10.106/j.diagmicrobio.2009.05.019.
3. David M., Gill M. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother 2008, 61:962-964.
4. Cascio A., Conti A., Sinardi L., Laria C., Angileri F.F., Stassi G., et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and systematic review of the literature. Int J Antimicrob Agents 2010, 14:572-579.
5. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically 2006, Clinical and Laboratory Standards Institute, Approved standard M7-A7, Clinical and Laboratory Standards Institute, Wayne PA.
6. Seirfert H., Dolzani L., Bressan R., van der Reijden T., van Strijen B., Stefanik D., et al. Standardization and interlaboratory reproducibility assessment pulsed-field electrophoresis generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005, 43:4328-4335.
7. Li J., Rayner C., Nation R., Owen R., Spelman D., Tan K., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006, 50:2946-2950.
8. Katragkou A., Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005, 43:4916-4917.
9. Kim B., Peleg A., Lodise T., Lipman J., Li J., Nation R., et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009, 9:245-255.
10. Kroeger L.A., Hovde L.B., Mitropoulos I.F., Schafer J., Rotschafer J.C. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2007, 51:3431-3433.
11. Fernandez-Reyes M., Rodriguez-Falcon M., Chiva C., Pachon J., Andreu D., Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: in a proteomic perspective. Proteomics 2009, 9:1632-1645.
12. Li J., Nation R., Owen R., Wong S., Spelman D., Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007, 45:594-598.